A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer
A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer
复制标题
DOI：
10.1016/j.radonc.2007.10.017
复制
发表时间：
2007-12-01
影响因子：
5.7
通讯作者：
Yamada, Shogo
中科院分区：
文献类型：
--
作者：
Koto, Masashi;Takai, Yoshihiro;Yamada, Shogo
背景和目的：I期非小细胞肺癌（NSCLC）患者接受常规放疗的结果不如手术治疗的患者。我们的目的是评估立体定向体部放射治疗（SBRT）在治疗I期NSCLC的临床结果。材料和方法：我们对31例I期NSCLC患者进行了SBRT。其中，20例在医学上无法手术，11例拒绝手术。19个肿瘤为T1期肿块，12个肿瘤为T2期。中位肿瘤大小为25 mm。SBRT的剂量为45戈伊/3次;然而，当肿瘤接近危险器官时，使用60戈伊/8次。这些剂量规定在中心的tumors.Results：观察所有患者的中位持续时间为32个月（范围，4-87个月）。31例中9例局部复发。T1和T2肿瘤的3年局部控制率分别为77.9%和40.0%。3年总生存率和病因特异性生存率分别为71.7%和83.5%。经内科治疗后症状改善，但仍有5例发生≥ 2级急性肺毒性。结论：SBRT治疗I期NSCLC安全有效。然而，T2肿瘤应考虑更强化的治疗方案。(c)2007爱思唯尔爱尔兰有限公司保留所有权利。
Background and purpose: The outcome of stage I non-small cell lung cancer (NSCLC) patients treated with conventional radiotherapy is inferior to that of patients treated surgically. We aimed to evaluate the clinical outcome of stereotactic body radiotherapy (SBRT) in the treatment of stage I NSCLC.Materials and methods: We performed SBRT for 31 stage I NSCLC patients. Of these, 20 were medically inoperable, and 11 refused surgery. Nineteen tumours were T1-stage masses, and 12 tumours were T2. Median tumour size was 25 mm. SBRT was administered as 45 Gy/3 fractions; however, when the tumour was close to an organ at risk, 60 Gy/8 fractions were used. These doses were prescribed at the centre of the tumours.Results: The median duration of observation for all patients was 32 months (range, 4-87 months). In 9 of the 31 cases, local recurrence was observed. The 3-year local control rates of T1 and T2 tumours were 77.9% and 40.0%, respectively. The 3-year overall and cause-specific survival rates were 71.7% and 83.5%, respectively. Although the symptoms improved with medical treatment, 5 patients developed acute pulmonary toxicity >= grade 2.Conclusions: SBRT is safe and effective for stage I NSCLC patients. However, a more intensive treatment regimen should be considered for T2 tumours. (c) 2007 Elsevier Ireland Ltd. All rights reserved.